The Prostate Cancer market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Prostate Cancer: An Overview
Prostate Cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. Prostate cancer is mainly caused due to changes in the DNA. These changes occur because of mutation in DNA. Prostate cancer is diagnosed when the cancer stage advances and symptoms are visible. However, early screening tests can be performed to find cancer in people before they show any symptoms.
Active Surveillance is the treatment of choice for patients with very low risk of prostate cancer to reduce or delay the morbidity of radical prostatectomy. However, surgery is a common choice for prostate cancer treatment if the disease has not spread outside the prostate gland. For prostate cancer, radical prostatectomy remains the gold standard for surgical management. Radical prostatectomy (RP) has been demonstrated to improve survival among patients with an intermediate risk of cancer-specific mortality and healthy life expectancy.
Prostate Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Prostate Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Prostate Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Prostate Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
Prostate Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prostate Cancer market or expected to be launched during the study period. The analysis covers the Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Prostate Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Prostate Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/prostate-cancer-market-insight
Prostate Cancer Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Prostate Cancer. Currently, Merck & Co. is leading the therapeutics market with its Prostate Cancer drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Prostate Cancer Therapeutics Market Include:
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca,Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and many others.
Prostate Cancer Drugs Covered in the Report Include:
Pembrolizumab: Merck & Co
Talazoparib: Pfizer
ODM-208: Orion
ZEN 3694: Zenith Epigenetics
EPI-7386: ESSA Pharma
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Prostate Cancer Competitive Intelligence Analysis
4. Prostate Cancer Market Overview at a Glance
5. Prostate Cancer Disease Background and Overview
6. Prostate Cancer Patient Journey
7. Prostate Cancer Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Prostate Cancer Unmet Needs
10. Key Endpoints of Prostate Cancer Treatment
11. Prostate Cancer Marketed Products
12. Prostate Cancer Emerging Drugs and Latest Therapeutic Advances
13. Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Prostate Cancer Market Outlook (In US, EU5, and Japan)
16. Prostate Cancer Access and Reimbursement Overview
17. KOL Views on the Prostate Cancer Market
18. Prostate Cancer Market Drivers
19. Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Solutions
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com
